Gary Woodnutt, Ph.D.
Senior Vice President of Translational Sciences and Preclinical Development
Dr. Woodnutt joined ContraFect in June 2021 as the Senior Vice President of Translational Sciences and Preclinical Development. He brings over 30 years of experience leading the discovery and development of innovative therapies ranging from antibiotics to novel protein-based therapeutics. Dr. Woodnutt will oversee the scientific strategy for the Company’s early stage assets and the performance of the extensive translational programs required to proceed into clinical trials. Additionally, he will directly impact and enable the regulatory strategy for the preclinical aspects of Investigational New Drug applications as well as the nonclinical sections of the potential Biologics License Application for exebacase.
Prior to joining ContraFect, Dr. Woodnutt served as Chief Scientific Officer of Tanabe Research Laboratories U.S.A. concentrating on the discovery and development of novel oncology therapies. Dr. Woodnutt also served as Chief Scientific Officer of Lpath where he led all discovery and development activities concerning the exploitation of monoclonal antibodies to bioactive lipids. Prior to this, Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer after the acquisition of CovX Pharmaceuticals where he served as Vice President of Biology Research. He began his career in the pharmaceutical industry with Beecham Pharmaceuticals, now GlaxoSmithKline plc, where worked in anti-infectives for more than 20 years, rising to the position of Vice President and Head of Biology in the Antimicrobial and Host Defense Group before joining Diversa Corporation as the Senior Vice President of Pharmaceutical Research and Development.
Dr. Woodnutt received his B.Sc. in Biochemistry and Physiology at the University of Leeds, UK and his Ph.D. in Biochemistry and Physiology from the University of Reading, UK. Dr. Woodnutt has over 40 peer-reviewed journal publications.